• 1
    Sullivan PB. Gastrointestinal disorders in children with neurodevelopmental disabilities. Dev Disabil Res Rev 2008; 14: 12836.
  • 2
    Bohmer CJM, Niezen-de Boer RC, Klinkenberg-Knol EC, Meuwissen SGM. Omeprazole – Therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 1998; 152: 11138.
  • 3
    Bohmer CJM, NiezendeBoer MC, KlinkenbergKnol EC, Tuynman HARE, Voskuil JH, Deville WLJM, Meuwissen SGM. Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy. Am J Gastroenterol 1997; 92: 14759.
  • 4
    Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44: 44166.
  • 5
    British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, and The Neonatal and Paediatric Pharmacists Group. BNF for Children. 2006.
  • 6
    Andersson T, Hassall E, Lundborg P, Shepherd R, Radke M, Marcon M, Dalvag A, Martin S, Behrens R, Koletzko S, Becker M, Drouin E, Gothberg G. Pharmacokinetics of orally administered omeprazole in children. Am J Gastroenterol 2000; 95: 31016.
    Direct Link:
  • 7
    Kearns GL, Andersson T, James LP, Gaedigk A, Kraynak RA, bdel-Rahman SM, Ramabadran K, van den Anker JN. Omeprazole disposition in children following single-dose administration. J Clin Pharmacol 2003; 43: 8408.
  • 8
    Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. Pharmacokinetics and Bioavailability of Omeprazole After Single and Repeated Oral-Administration in Healthy-Subjects. Br J Clin Pharmacol 1990; 29: 55763.
  • 9
    Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors – Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 928.
  • 10
    Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR, Guo YZ. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol 2006; 62: 10712.
  • 11
    Sharma VK, Peyton B, Spears T, Raufman JP, Howden CW. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Alimentary Pharmacology & Therapeutics 2000; 14: 88792.
  • 12
    AstraZeneca UK Limited. Summary of Product Characteristics: Losec MUPS Tablets 10 mg, 20 mg & 40 mg (consulted via the electronic Medicines Compendium). Available at (last accessed 30 September 2010).
  • 13
    Howden CW. Clinical-pharmacology of omeprazole. Clin Pharmacokinet 1991; 20: 3849.
  • 14
    Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole – a gastric proton pump inhibitor – on pentagastrin stimulated acid-secretion in man. Gut 1983; 24: 2706.
  • 15
    Stedman CAM, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 96378.
  • 16
    Faure C, Michaud T, Shaghaghi EK, Popon M, Turck T, Navarro J, Jacqz-Aigrain E. Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. J Pediatr Gastroenterol Nutr 2001; 33: 1448.
  • 17
    Olsen KM, Bergman KL, Kaufman SS, Rebuck JA, Collier DS. Omeprazole pharmacodynamics and gastric acid suppression in critically ill pediatric transplant patients. Pediatr Crit Care Med 2001; 2: 2327.
  • 18
    Tuleu C, renas-Lopez S, Robinson C, McCarthy D, Paget RIJ, Tibby S, Taylor KMG. ‘Poppy seeds’ in stomach aspirates: is oral omeprazole extemporaneous dispersion bioavailable? Eur J Pediatr 2008; 167: 8235.